Who is sponsoring NCT02790632?

NCT02790632 is sponsored by Edge Therapeutics Inc.

What drugs are being tested in NCT02790632?

Interventions in NCT02790632: EG-1962 (nimodipine microparticles), Enteral Nimodipine.

What condition does NCT02790632 study?

NCT02790632 studies Subarachnoid Hemorrhage, Aneurysmal.

Is NCT02790632 still recruiting?

NCT02790632 is currently terminated. Last updated 24 July 2018.

Last reviewed 2018-07-24 · How we verify

NCT02790632: NEWTON2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Terminated Phase 3 Last updated 24 July 2018

What this trial tests

Phase 3 trial testing EG-1962 (nimodipine microparticles) in Subarachnoid Hemorrhage, Aneurysmal in 374 participants. Terminated before completion.

Timeline

1 July 2016

Primary endpoint
1 June 2018

1 June 2018

Quick facts

Lead sponsor	Edge Therapeutics Inc
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	374
Start date	1 July 2016
Primary completion	1 June 2018
Estimated completion	1 June 2018
Sites	79 locations across United States, Australia, Austria, Canada, Czechia, Finland, Germany, Hong Kong

Drugs / interventions tested

EG-1962 (nimodipine microparticles) — full drug profile →
Enteral Nimodipine — full drug profile →

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →

Sponsor

Edge Therapeutics Inc — full company profile →

Who can join

Adults 18 to 75, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale [Primary Efficacy Endpoint]
Time frame: 90 Days
Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale (GOSE) at Day 90

Sponsor's own description

This study compares EG-1962 to enteral nimodipine in the treatment of aneurysmal subarachnoid hemorrhage.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Nimodipine Reappraised: An Old Drug With a Future.
Carlson AP, Hänggi D, Macdonald RL, Shuttleworth CW. · · 2020 · cited 97× · PMID 31560289 · DOI 10.2174/1570159x17666190927113021
Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
Carlson AP, Hänggi D, Wong GK, Etminan N, et al · · 2020 · cited 44× · PMID 32138631 · DOI 10.1161/strokeaha.119.027396
Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to
Hänggi D, Etminan N, Mayer SA, Aldrich EF, et al · · 2019 · cited 19× · PMID 30014184 · DOI 10.1007/s12028-018-0575-z
MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats.
Christensen ST, Johansson SE, Radziwon-Balicka A, Warfvinge K, et al · · 2019 · cited 11× · PMID 30978262 · DOI 10.1371/journal.pone.0215398

Verify or expand the search:

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02790632 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Edge Therapeutics Inc
Last refreshed: 24 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02790632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing